InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,572.48
(
0.57%
)
Post# of 252201
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: jq1234 post# 162658

Monday, 06/17/2013 11:16:53 PM

Monday, June 17, 2013 11:16:53 PM

Post# of 252201
jq appreciate your thoroughness, hard to RECIST data...

I get your point about Criz...the heavily pre-treated study A only yielded 50% ORR, so LDK's 60% ORR starting to look more impressive. Still think LDK's toxicity is a little too retro.

I wouldn't assume anything about '113 in Criz-naive with only 4 patients. I've grown to be more trusting of Ariad's conservative data presentations over Novartis-types, so I'm still optimistic that '113 will have 70%+ RECIST ORR in Criz-resistant at ESMO.

Did you know if Chugai has any RECIST confirmed data?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up